GSK to nearly double cancer drugs in late-stage trials next year: WSJ
Magdalena Wygralak
GSK (GSK) is making additional investments in oncology, with the number of cancer drugs in late-stage development expected to nearly double next year, The Wall Street Journal reported on Tuesday, citing one of its leading scientists.
Hesham Abdullah, head of oncology R&D at GSK (GSK), said that the British drugmaker is doubling down in oncology to accelerate its return to the field it exited nearly a decade ago.
“Right now we have five approved [cancer] medicines; I think probably in a few weeks’ time there’ll be six,” Abdullah said. “We have a clinical-stage portfolio of about 15 assets that’s probably going to, I would say, close to double in 2027.”
“We’re seeing that there’s a continued rise in the incidence of cancer across multiple different patient segments,” he noted, adding, “One of the biggest pushes for us in thinking about getting back into oncology was addressing this unmet need.”
Recommended For You
Register for free to keep reading.
Create a free account to get unlimited breaking news and alerts when your stocks move.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.